Literature DB >> 17029075

Inhibitory effect of mizoribine on matrix metalloproteinase-1 production in synovial fibroblasts and THP-1 macrophages.

Binbin Zhong1, Michiko Tajima, Hidenari Takahara, Hiromi Nochi, Koichi Tamoto, Naoto Tamura, Shigeto Kobayashi, Yoshifumi Tamura, Makoto Ikeda, Tomohiro Akimoto, Shinichi Yoshino, Hiroshi Hashimoto.   

Abstract

To investigate the mechanism of antirheumatic action of mizoribine (MZR), we examined the expression of matrix metalloproteinase-1 (MMP-1) and MMP-3 utilizing THP-1 derived macrophage-like cells (THP-1 macrophages) and human synovial fibroblasts (SFs). The cells were respectively stimulated with lipopolysaccharide (LPS) and interleukin-1beta in the presence or absence of MZR in vitro. The concentrations of MMP-1 and MMP-3 in the supernatant were measured by enzyme-linked immunosorbent assay. The secretion of MMP-1 from SFs, as well as THP-1 macrophages, was inhibited by MZR in a dose-dependent manner. Furthermore, a quantitative real-time polymerase chain reaction revealed that MZR decreased the expression of MMP-1 messenger RNA. These findings may be an explanation for the clinical effect of MZR in patients with rheumatoid arthritis.

Entities:  

Year:  2005        PMID: 17029075     DOI: 10.1007/s10165-005-0406-x

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  2 in total

1.  Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy.

Authors:  Yohei Ikezumi; Toshiaki Suzuki; Tamaki Karasawa; Hiroshi Kawachi; David J Nikolic-Paterson; Makoto Uchiyama
Journal:  Pediatr Nephrol       Date:  2007-11-24       Impact factor: 3.714

2.  The immunosuppressive agent mizoribine monophosphate is an inhibitor of the human RNA capping enzyme.

Authors:  Frédéric Picard-Jean; Isabelle Bougie; Satoshi Shuto; Martin Bisaillon
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.